AIkido Pharma, Inc. Hires Carlos Aldavero to Lead Financial Services Subsidiary


Morgan Stanley Executive joins Dominari Financial, Inc. on July 22, 2022

NEW YORK, July 21, 2022 /PRNewswire/ — Anthony Hayes, CEO of AIkido Pharma Inc. (NASDAQ: AIKI) (“AIkido” or the “Company”), announced the hiring of Carlos Aldavero as President of Dominari Financial, the subsidiary of Aikido’s recently created financial services. Mr. Aldavero joins Dominari from Morgan Stanley where he was an associate complex director overseeing one of the venerable Wall St. company’s largest and most profitable business units.

In this newly created role, Mr. Aldavero will be responsible for identifying strategic assets in the fintech and financial services sector for acquisition and investment while creating an organizational structure that leverages the synergies inherent in a business model. accretive business. He will report to Mr. Hayes.

“We are thrilled to have someone with Carlos’ extensive financial services experience and deep skillset take on this key role in our organization,” said Hayes. “We are confident that he will provide the forward-thinking leadership that will help make our recently created financial services division a significant contributor to AIkido’s bottom line and help us increase the overall value of our business. Carlos will also work in working closely with me to identify other key hires and build a world-class leadership team for the financial services division.”

Mr. Aldavero is a highly respected and sought-after executive who has held senior positions at some of the leading financial institutions over a long and distinguished career, including Merrill Lynch, Pierce, Fenner & Smith Inc., Copernicus Institutional Advisors LLC and Deutsche Bank, among others. “I want to thank Anthony and the AIkido Board of Directors for this amazing opportunity to be part of an organization that embraces innovation and for the chance to build a dynamic financial services organization that will be at the forefront of trends. emerging in the industry,” says Aldavero. His first day should be July 22, 2022.

Dominari Financial, Inc. was established by AIkido to make strategic investments and revenue-generating asset acquisitions in the areas of wealth management, investment banking, alternative investments and asset management . Dominari is key to AIkido’s long-term goal of diversifying beyond biotechnology to reduce volatility and mitigate risk while increasing revenue and return on investment for shareholders. Dominari is based in New York.

Dominari Financial, Inc. Mission Statement:

Dominari is a dynamic, forward-thinking financial services holding company that creates wealth for all stakeholders by capitalizing on emerging trends in the financial services industry and identifying future opportunities at an early stage that will generate a high return for investors.

About AIkido Pharma Inc.

AIkido Pharma Inc. was originally established in 1967 and is a biotechnology company with a diverse portfolio of small molecule anticancer and antiviral therapeutics. The Company’s platform consists of patented technology sourced from leading universities and researchers, and we are currently developing an innovative therapeutic drug platform through strong partnerships with educational institutions. world-renowned, including the University of Texas in Austin and the University of Maryland at Baltimore. Our diverse pipeline of therapeutics includes therapies for pancreatic cancer and prostate cancer. We are constantly looking to expand our pipeline to address unmet medical needs in oncology. The Company is also developing a broad-spectrum antiviral platform that could potentially inhibit the replication of several viruses, including influenza virus, SARS-CoV (coronavirus), MERS-CoV, Ebola virus and Marburg virus.

Forward-looking statements

Certain statements contained in this press release constitute “forward-looking statements” within the meaning of the federal securities laws. Words such as “may”, “could”, “will”, “should”, “believe”, “expect”, “anticipate”, “estimate”, “continue”, “predict”, “plan” , “project”, “” Although the Company believes that these forward-looking statements are reasonable, undue reliance should not be placed on these forward-looking statements, which are based on information available to us as of the date of this release. These forward-looking statements are based on current estimates and assumptions and are subject to various risks and uncertainties, including, without limitation, those set forth in the Company’s filings with the SEC, without limitation to risk associated with its activities contained therein. Therefore, actual results could differ materially. The Company expressly disclaims any obligation to update or change any statements, whether as a result of new information, future events or otherwise, except as required by law.


Investor Relations:

R.I. Hayden
Brett MaasManaging partner
Telephone: (646) 536-7331
E-mail: [email protected]

AIkido Pharma Inc.
Phone: 212-745-1373
E-mail: [email protected]

SOURCEAIkido Pharma Inc.


Comments are closed.